Glucose-Dependent Insulinotropic Peptide Prevents Serum Deprivation-Induced Apoptosis in Human Bone Marrow-Derived Mesenchymal Stem Cells and Osteoblastic Cells

Stem Cell Reviews and Reports

Volumn 11, Issue 6, 2015, Pages 841-851

  Berlier, J L ^a   Kharroubi, I ^a   Zhang, J ^a   Dalla Valle, A ^a   Rigutto, S ^a   Mathieu, M ^a   Gangji, V ^a,b   Rasschaert, J ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b ERASME HOSPITAL   (Belgium)

Author keywords

Apoptosis; cAMP accumulation; Glucose dependent insulinotropic peptide; Human bone marrow derived mesenchymal stem cells; Serum deprivation

Indexed keywords

ADENYLATE CYCLASE; CASPASE 3; CASPASE 7; GASTRIC INHIBITORY POLYPEPTIDE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BCL 2; PROTEIN KINASE B; CYCLIC AMP; GASTRIC INHIBITORY POLYPEPTIDE RECEPTOR; HORMONE RECEPTOR; SERUM-FREE MEDIUM;

ADULT; APOPTOSIS; ARTICLE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CAMP ASSAY; CELL DIFFERENTIATION; CELL VIABILITY; COLONY FORMING UNIT; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MRNA EXPRESSION ASSAY; OSTEOBLAST; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEM CELL TRANSPLANTATION; SURVIVAL RATE; WESTERN BLOTTING; BONE MARROW CELL; CELL CULTURE; CELL CULTURE TECHNIQUE; CELL PROLIFERATION; CELL SURVIVAL; CYTOLOGY; DRUG EFFECTS; ENZYME ACTIVATION; MESENCHYMAL STROMA CELL; METABOLISM; PHARMACOLOGY; PHYSIOLOGY; SERUM-FREE MEDIUM; SIGNAL TRANSDUCTION;

APOPTOSIS; BONE MARROW CELLS; CASPASE 3; CASPASE 7; CELL CULTURE TECHNIQUES; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CULTURE MEDIA, SERUM-FREE; CYCLIC AMP; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GASTRIC INHIBITORY POLYPEPTIDE; HUMANS; MAP KINASE SIGNALING SYSTEM; MESENCHYMAL STROMAL CELLS; OSTEOBLASTS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, GASTROINTESTINAL HORMONE;

EID: 84947613424     PISSN: 15508943     EISSN: 15586804     Source Type: Journal    
DOI: 10.1007/s12015-015-9616-6     Document Type: Article

References (66)

1. Satija, N. K., Gurudutta, G. U., Sharma, S., et al. (2007). Mesenchymal stem cells: molecular targets for tissue engineering. Stem Cells and Development, 16(1), 7–23.
2. Ra, J. C., Kang, S. K., Shin, I. S., et al. (2011). Stem cell treatment for patients with autoimmune disease by systemic infusion of culture-expanded autologous adipose tissue derived mesenchymal stem cells. Journal of Translational Medicine, 9(1), 181.
3. Lee, H. J., Lee, J. K., Lee, H., et al. (2010). The therapeutic potential of human umbilical cord blood-derived mesenchymal stem cells in Alzheimer’s disease. Neuroscience Letters, 481(1), 30–35.
4. Lee, J. K., Jin, H. K., Endo, S., Schuchman, E. H., Carter, J. E., & Bae, J.-S. (2010). Intracerebral transplantation of bone marrow-derived mesenchymal stem cells reduces amyloid-beta deposition and rescues memory deficits in Alzheimer’s disease mice by modulation of immune responses. Stem Cells, 28(2), 329–343.
5. Kon, E., Filardo, G., Roffi, A., et al. (2012). Bone regeneration with mesenchymal stem cells. Clinical Cases in Mineral and Bone Metabolism, 9(1), 24–27.
6. Undale, A. H., Westendorf, J. J., Yaszemski, M. J., & Khosla, S. (2009). Mesenchymal stem cells for bone repair and metabolic bone diseases. Mayo Clinic Proceedings, 84(10), 893–902.
7. Horwitz, E. M., Prockop, D. J., Fitzpatrick, L. A., et al. (1999). Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nature Medicine, 5(3), 309–313.
8. Hauzeur, J.-P., & Gangji, V. (2010). Phases 1–3 clinical trials using adult stem cells in osteonecrosis and nonunion fractures. Stem Cells International, 26, 410170.
9. Chamberlain, G., Fox, J., Ashton, B., & Middleton, J. (2007). Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells, 25(11), 2739–2749.
10. Dimarakis, I., & Levicar, N. (2006). Cell culture medium composition and translational adult bone marrow-derived stem cell research. Stem Cells, 24(5), 1407–1408.
11. Chen, J., Baydoun, A. R., Xu, R., et al. (2008). Lysophosphatidic acid protects mesenchymal stem cells against hypoxia and serum deprivation-induced apoptosis. Stem Cells, 26(1), 135–145.
12. Geng, Y.-J. (2003). Molecular mechanisms for cardiovascular stem cell apoptosis and growth in the hearts with atherosclerosis coronary disease and ischemic heart failure. Annals of the New York Academy of Sciences, 1010, 687–697.
13. Fukuda, K., & Yuasa, S. (2006). Stem cells as a source of regenerative cardiomyocytes. Circulation Research, 98(8), 1002–1013.
14. Mathieu, M., Rigutto, S., Ingels, A., et al. (2013). Decreased pool of mesenchymal stem cells is associated with altered chemokines serum levels in atrophic nonunion fractures. Bone, 53(2), 391–398.
15. Dimitriou, R., Jones, E., McGonagle, D., & Giannoudis, P. V. (2011). Bone regeneration: current concepts and future directions. BMC Medicine, 9(1), 66.
16. Kaushik, A. P., Das, A., & Cui, Q. (2012). Osteonecrosis of the femoral head: an update in year 2012. World Journal of Orthopedics, 3(5), 49–57.
17. Gangji, V., & Hauzeur, J.-P. (2005). Treatment of osteonecrosis of the femoral head with implantation of autologous bone-marrow cells. Journal of Bone and Joint Surgery, 87(A), 106–112.
18. Chim, S. M., Tickner, J., Chow, S. T., et al. (2013). Angiogenic factors in bone local environment. Cytokine and Growth Factor Reviews, 24(3), 297–310.
19. Potier, E., Ferreira, E., Meunier, A., Sedel, L., Logeart-Avramoglou, D., & Petite, H. (2007). Prolonged hypoxia concomitant with serum deprivation induces massive human mesenchymal stem cell death. Tissue Engineering, 13(6), 1325–1331.
20. Baggio, L. L., & Drucker, D. J. (2007). Biology of incretins: GLP-1 and GIP. Gastroenterology, 132(6), 2131–2157.
21. Holst, J. J., Vilsbøll, T., & Deacon, C. F. (2009). The incretin system and its role in type 2 diabetes mellitus. Molecular and Cellular Endocrinology, 297(1–2), 127–136.
22. Ehses, J. A., Casilla, V. R., Doty, T., et al. (2003). Glucose-dependent insulinotropic polypeptide promotes -(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase. Endocrinology, 144(10), 4433–4445.
23. Kim, S.-J., Winter, K., Nian, C., Tsuneoka, M., Koda, Y., & McIntosh, C. H. S. (2005). Glucose-dependent insulinotropic polypeptide (GIP) stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1, and down-regu. Journal of Biological Chemistry, 280(23), 22297–22307.
24. Kaplan, A. M., & Vigna, S. R. (1994). Gastric inhibitory polypeptide (GIP) binding sites in rat brain. Peptides, 15(2), 297–302.
25. Yip, R. G.-C., Boylan, M., Kieffer, T., & Wolfe, M. M. (1998). Functional GIP receptors are present on adipocytes. Endocrinology, 139(9), 4004–4007.
26. Bollag, R. J., Zhong, Q., Phillips, P., et al. (2000). Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors. Endocrinology, 141(3), 1228–1235.
27. Dicembrini, I., Mannucci, E., & Rotella, C. M. (2012). Bone: incretin hormones perceiver or receiver? Experimental Diabetes Research, 2012, 519784.
28. Tsukiyama, K., Yamada, Y., Yamada, C., et al. (2006). Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion. Molecular Endocrinology, 20(7), 1644–1651.
29. Zhong, Q., Itokawa, T., Sridhar, S., et al. (2007). Effects of glucose-dependent insulinotropic peptide on osteoclast function. American Journal of Physiology - Endocrinology and Metabolism, 292, 543–548.
30. Xie, D., Zhong, Q., Ding, K.-H., et al. (2007). Glucose-dependent insulinotropic peptide-overexpressing transgenic mice have increased bone mass. Bone, 40(5), 1352–1360.
31. Xie, D., Cheng, H., Hamrick, M., et al. (2005). Glucose-dependent insulinotropic polypeptide receptor knockout mice have altered bone turnover. Bone, 37(6), 759–769.
32. Gaudin-Audrain, C., Irwin, N., Mansur, S., et al. (2013). Glucose-dependent insulinotropic polypeptide receptor deficiency leads to modifications of trabecular bone volume and quality in mice. Bone, 53(1), 221–230.
33. Mieczkowska, A., Irwin, N., Flatt, P. R., Chappard, D., & Mabilleau, G. (2013). Glucose-dependent insulinotropic polypeptide (GIP) receptor deletion leads to reduced bone strength and quality. Bone, 56, 337–342.
34. Ding, K., Shi, X., Zhong, Q., et al. (2008). Impact of glucose-dependent insulinotropic peptide on age-induced bone loss. Journal of Bone and Mineral Research, 23(4), 536–543.
35. Van Sande, J., Dequanter, D., Lothaire, P., Massart, C., Dumont, J. E., & Erneux, C. (2006). Thyrotropin stimulates the generation of inositol 1,4,5-trisphosphate in human thyroid cells. Journal of Clinical Endocrinology and Metabolism, 91(3), 1099–1107.
36. Minamide, L. S., & Bamburg, J. R. (1990). A filter paper dye-binding assay for quantitative determination of protein without interference from reducing agents or detergents. Analytical Biochemistry, 190(1), 66–70.
37. Yang, D.-C., Tsay, H.-J., Lin, S.-Y., et al. (2008). cAMP/PKA regulates osteogenesis, adipogenesis and ratio of RANKL/OPG mRNA expression in mesenchymal stem cells by suppressing leptin. PLoS One, 3(2), e1540.
38. Jhala, U. S., Canettieri, G., Screaton, R. A., et al. (2003). cAMP promotes pancreatic beta-cell survival via CREB-mediated induction of IRS2. Genes and Development, 17(13), 1575–1580.
39. Siddappa, R., Martens, A., Doorn, J., et al. (2008). cAMP/PKA pathway activation in human mesenchymal stem cells in vitro results in robust bone formation in vivo. Proceedings of the National Academy of Sciences of the United States of America, 105(20), 7281–7286.
40. Kim, S.-J., Nian, C., Widenmaier, S. B., & McIntosh, C. H. S. (2008). Glucose-dependent insulinotropic polypeptide-mediated up-regulation of beta-cell antiapoptotic Bcl-2 gene expression is coordinated by cyclic AMP (cAMP) response element binding protein (CREB) and cAMP-responsive CREB coactivator 2. Molecular and Cellular Biology, 28(5), 1644–1656.
41. Lu, Z., & Xu, S. (2006). ERK1/2 MAP kinases in cell survival and apoptosis. IUBMB Life, 58(11), 621–631.
42. Liang, M., Russell, G., & Hulley, P. A. (2008). Bim, Bak, and Bax regulate osteoblast survival. Journal of Bone and Mineral Research, 23(5), 610–620.
43. Downward, J. (2004). PI 3-kinase, Akt and cell survival. Seminars in Cell and Developmental Biology, 15(2), 177–182.
44. Widenmaier, S. B., Ao, Z., Kim, S.-J., Warnock, G., & McIntosh, C. H. S. (2009). Suppression of p38 MAPK and JNK via Akt-mediated inhibition of apoptosis signal-regulating kinase 1 constitutes a core component of the beta-cell pro-survival effects of glucose-dependent insulinotropic polypeptide. Journal of Biological Chemistry, 284(44), 30372–30382.
45. Trümper, A., Trümper, K., & Hörsch, D. (2002). Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells. Journal of Endocrinology, 174(2), 233–246.
46. Youle, R. J., & Strasser, A. (2008). The BCL-2 protein family: opposing activities that mediate cell death. Nature Reviews Molecular Cell Biology, 9(1), 47–59.
47. Jung, S., Panchalingam, K. M., Rosenberg, L., & Behie, L. A. (2012). Ex vivo expansion of human mesenchymal stem cells in defined serum-free media. Stem Cells International, 2012, 123030.
48. Selvaggi, T. A., Walker, R. E., & Fleisher, T. A. (1997). Development of antibodies to fetal calf serum with arthus-like reactions in human immunodeficiency virus-infected patients given syngeneic lymphocyte infusions. Blood, 89(3), 776–779.
49. Sotiropoulou, P. A., Perez, S. A., Salagianni, M., Baxevanis, C. N., & Papamichail, M. (2006). Cell culture medium composition and translational adult bone marrow-derived stem cell research. Stem Cells, 24(5), 1409–1410.
50. Tonti, G. A., & Mannello, F. (2008). From bone marrow to therapeutic applications: different behaviour and genetic/epigenetic stability during mesenchymal stem cell expansion in autologous and foetal bovine sera? International Journal of Developmental Biology, 52(8), 1023–1032.
51. Schnoke, M., Midura, S. B., & Midura, R. J. (2009). Parathyroid hormone suppresses osteoblast apoptosis by augmenting DNA repair. Bone, 45(3), 590–602.
52. Yin, Q., Jin, P., Liu, X., et al. (2011). SDF-1α inhibits hypoxia and serum deprivation-induced apoptosis in mesenchymal stem cells through PI3K/Akt and ERK1/2 signaling pathways. Molecular Biology Reports, 38(1), 9–16.
53. Mrak, E., Guidobono, F., Moro, G., Fraschini, G., Rubinacci, A., & Villa, I. (2010). Calcitonin gene-related peptide (CGRP) inhibits apoptosis in human osteoblasts by β-catenin stabilization. Journal of Cellular Physiology, 225(3), 701–708.
54. Pacheco-Pantoja, E. L., Ranganath, L. R., Gallagher, J. A., Wilson, P. J., & Fraser, W. D. (2011). Receptors and effects of gut hormones in three osteoblastic cell lines. BMC Physiology, 11(1), 12.
55. Zhu, W., Chen, J., Cong, X., Hu, S., & Chen, X. (2006). Hypoxia and serum deprivation-induced apoptosis in mesenchymal stem cells. Stem Cells, 24(2), 416–425.
56. Li, Z., Wei, H., Liu, X., Hu, S., Cong, X., & Chen, X. (2010). LPA rescues ER stress-associated apoptosis in hypoxia and serum deprivation-stimulated mesenchymal stem cells. Journal of Cellular Biochemistry, 111(4), 811–820.
57. Solmesky, L. J., Abekasis, M., Bulvik, S., & Weil, M. (2009). Bone morphogenetic protein signaling is involved in human mesenchymal stem cell survival in serum-free medium. Stem Cells and Development, 18(9), 1283–1292.
58. Bal, T., Nazli, C., Okcu, A., Duruksu, G., Karaöz, E., Kizilel, S. (2014). Mesenchymal stem cells and ligand incorporation in biomimetic poly(ethylene glycol) hydrogels significantly improve insulin secretion from pancreatic islets. Journal of Tissue Engineering and Regenerative Medicine. doi:10.1002/term.1965.
59. Kim, W., & Egan, J. M. (2008). The role of incretins in glucose homeostasis and diabetes treatment. Pharmacological Reviews, 60(4), 470–512.
60. Insel, P. A., Zhang, L., Murray, F., Yokouchi, H., & Zambon, A. C. (2012). Cyclic AMP is both a pro-apoptotic and anti-apoptotic second messenger. Acta Physiologica (Oxford, England), 204(2), 277–287.
61. Martin, M. C., Dransfield, I., Haslett, C., & Rossi, A. G. (2001). Cyclic AMP regulation of neutrophil apoptosis occurs via a novel protein kinase A-independent signaling pathway. Journal of Biological Chemistry, 276(48), 45041–45050.
62. Follin-Arbelet, V., Hofgaard, P. O., Hauglin, H., et al. (2011). Cyclic AMP induces apoptosis in multiple myeloma cells and inhibits tumor development in a mouse myeloma model. BMC Cancer, 11(1), 301.
63. Zhao, Z., Kapoian, T., Shepard, M., & Lianos, E. A. (2002). Adenosine-induced apoptosis in glomerular mesangial cells. Kidney International, 61, 1276–1285.
64. Lamkanfi, M., & Kanneganti, T.-D. (2010). Caspase-7: a protease involved in apoptosis and inflammatio. International Journal of Biochemistry and Cell Biology, 42, 21–24.
65. Brentnall, M., Rodriguez-Menocal, L., De Guevara, R. L., Cepero, E., & Boise, L. H. (2013). Caspase-9, caspase-3 and caspase-7 have distinct roles during intrinsic apoptosis. BMC Cell Biology, 14(32), 1.
66. Wong, W. W.-L., & Puthalakath, H. (2008). Bcl-2 family proteins: the sentinels of the mitochondrial apoptosis pathway. IUBMB Life, 60(6), 390–397.